tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Toxocariasis D014120 3 associated lipids
Translocation, Genetic D014178 20 associated lipids
Tremor D014202 15 associated lipids
Trichomonas Infections D014245 3 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Trypanosomiasis D014352 5 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Ulcer D014456 16 associated lipids
Uremia D014511 33 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Urination Disorders D014555 9 associated lipids
Urticaria D014581 13 associated lipids
Uveitis D014605 14 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Vascular Diseases D014652 16 associated lipids
Vasculitis D014657 14 associated lipids
Venous Insufficiency D014689 2 associated lipids
Viremia D014766 4 associated lipids
Vision Disorders D014786 10 associated lipids
Vitiligo D014820 2 associated lipids
Vomiting D014839 21 associated lipids
West Nile Fever D014901 1 associated lipids
Wounds, Stab D014951 3 associated lipids
Dementia, Vascular D015140 7 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Carcinoma, Merkel Cell D015266 2 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Tumor Lysis Syndrome D015275 2 associated lipids
Discitis D015299 2 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Scleritis D015423 3 associated lipids
Reperfusion Injury D015427 65 associated lipids
Weight Gain D015430 101 associated lipids
Weight Loss D015431 56 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Histiocytosis D015614 2 associated lipids
HIV Infections D015658 20 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Eye Infections, Fungal D015821 2 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Vestibular Diseases D015837 2 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Uveitis, Posterior D015866 5 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
AIDS-Associated Nephropathy D016263 1 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Granuloma Annulare D016460 1 associated lipids
Sweet Syndrome D016463 1 associated lipids
Fungemia D016469 2 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Foot Ulcer D016523 4 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Critical Illness D016638 13 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Meningitis, Fungal D016921 1 associated lipids
Liver Failure D017093 5 associated lipids
IgA Deficiency D017098 2 associated lipids
IgG Deficiency D017099 1 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Polymyositis D017285 1 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Skin Diseases, Papulosquamous D017444 2 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Acneiform Eruptions D017486 3 associated lipids
Hyperpigmentation D017495 11 associated lipids
Hypopigmentation D017496 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Porokeratosis D017499 1 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Peterson LB et al. A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus. 1998 Transplantation pmid:9448137
Connor A et al. Generic tacrolimus in renal transplantation: trough blood concentration as a surrogate for drug exposure. 2012 Transplantation pmid:23318306
Plock JA et al. Adipose- and Bone Marrow-Derived Mesenchymal Stem Cells Prolong Graft Survival in Vascularized Composite Allotransplantation. 2015 Transplantation pmid:26102613
Gurk-Turner C et al. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. 2008 Transplantation pmid:18497682
Rolles K et al. A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin. 1999 Transplantation pmid:10551650
Pirsch JD Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group. 1999 Transplantation pmid:10551653
Taber DJ et al. Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. 2017 Transplantation pmid:28658199
Diémé B et al. Assessing the metabolic effects of calcineurin inhibitors in renal transplant recipients by urine metabolic profiling. 2014 Transplantation pmid:24598938
Mañez R et al. Fluconazole therapy in transplant recipients receiving FK506. 1994 Transplantation pmid:7515201
Hirose R et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. 2000 Transplantation pmid:10670644
Han DH et al. Effect of sirolimus on calcineurin inhibitor-induced nephrotoxicity using renal expression of KLOTHO, an antiaging gene. 2010 Transplantation pmid:20562737
Hirano Y et al. Morphological and functional changes of islets of Langerhans in FK506-treated rats. 1992 Transplantation pmid:1373536
Yasunami Y et al. FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. 1990 Transplantation pmid:1691535
Sindhi R et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. 2001 Transplantation pmid:11571449
Jain A et al. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. 2000 Transplantation pmid:11087149
Shibutani S et al. Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. 2005 Transplantation pmid:15849542
Tory R et al. Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations. 2009 Transplantation pmid:19584682
Weiler N et al. Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. 2010 Transplantation pmid:21048536
Koomans HA and Ligtenberg G Mechanisms and consequences of arterial hypertension after renal transplantation. 2001 Transplantation pmid:11585243
Trimarchi HM et al. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. 1999 Transplantation pmid:10071024
Gaber AO et al. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial. 2008 Transplantation pmid:19005398
Luan FL et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. 2002 Transplantation pmid:12042641
Hoogduijn MJ et al. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. 2008 Transplantation pmid:19005411
Hadley S et al. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. 1995 Transplantation pmid:7535482
Gill JS et al. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. 2010 Transplantation pmid:20098280
Alessiani M et al. Combined immunosuppressive therapy with tacrolimus and mycophenolate mofetil for small bowel transplantation in pigs. 1996 Transplantation pmid:8830816
Pascual J et al. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. 2009 Transplantation pmid:19136902
Vossen M et al. Bone quality in swine composite tissue allografts: effects of combination immunotherapy. 2005 Transplantation pmid:16123723
Irish W et al. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. 2003 Transplantation pmid:14688516
Furlan V et al. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. 1995 Transplantation pmid:7537398
Akst LM et al. Induction of tolerance in a rat model of laryngeal transplantation. 2003 Transplantation pmid:14688529
Lauria MW et al. Metabolic long-term follow-up of functioning simultaneous pancreas-kidney transplantation versus pancreas transplantation alone: insights and limitations. 2010 Transplantation pmid:20061923
Koch R et al. Cyclosporine A-induced achalasia-like esophageal motility disorder in a liver transplant recipient: successful conversion to tacrolimus. 2003 Transplantation pmid:12973123
Paty BW et al. Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. 2002 Transplantation pmid:11884930
Dell'Antonio G and Randhawa PS "Striped" pattern of medullary ray fibrosis in allograft biopsies from kidney transplant recipients maintained on tacrolimus. 1999 Transplantation pmid:10030300
Ueda M et al. A proposal of FK506 optimal dosing in living related liver transplantations. 1995 Transplantation pmid:7544035
Stevens C et al. The effects of immunosuppressive agents on in vitro production of human immunoglobulins. 1991 Transplantation pmid:1710843
Paolillo JA et al. Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. 2001 Transplantation pmid:11213069
Mathew A et al. Reversal of steroid-resistant rejection in renal allograft recipients using FK506. 1995 Transplantation pmid:7482730
Lauzurica R et al. Tacrolimus-associated severe bilateral corneal ulcer after renal transplantation. 2002 Transplantation pmid:11923710
Mayer AD et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. 1997 Transplantation pmid:9275110
Platz KP et al. Causes of death following liver transplantation in FK 506- and cyclosporine-treated patients. 1994 Transplant. Proc. pmid:7527952
Felldin M et al. Rescue therapy with Tacrolimus (FK506) in renal transplant recipients--a multicenter analysis. 1995 Transplant. Proc. pmid:8540032
Kahan BD Cyclosporine: the base for immunosuppressive therapy--present and future. 1993 Transplant. Proc. pmid:7679819
Tze WJ et al. Prolongation of pig islet xenograft survival in rats by local immunosuppression with FK 506. 1994 Transplant. Proc. pmid:7513471
Yabuuchi H et al. Prominent prolongation of islet xenograft survival in combination therapy with FK 506 and 15-deoxyspergualin. 1991 Transplant. Proc. pmid:1703718
McCauley J et al. The effects of FK 506 on renal function after liver transplantation. 1990 Transplant. Proc. pmid:1689887
Kanter J et al. Cytomegalovirus infection renal transplant recipients: risk factors and outcome. 2009 Jul-Aug Transplant. Proc. pmid:19715860
Rafael-Valdivia L et al. How long should initiation of calcineurin inhibitors be delayed to protect renal function in liver transplantation? 2011 Transplant. Proc. pmid:21486577
McDiarmid S et al. One hundred children treated with tacrolimus after primary orthotopic liver transplantation. 1998 Transplant. Proc. pmid:9636564
Santos T et al. New Recipes With Known Ingredients: Combined Therapy of Everolimus and Low-dose Tacrolimus in De Novo Renal Allograft Recipients. 2015 Transplant. Proc. pmid:26036483
Luk JM et al. Immunosuppressive effects of Tripterygium wilfordii polysaccharide on LPS-stimulated human monocytes. 2000 Transplant. Proc. pmid:11120045
Abu-Elmagd KM et al. Monitoring and treatment of intestinal allograft rejection in humans. 1993 Transplant. Proc. pmid:7680150
Higuchi K et al. FK506 induces the atrophy of enteric ganglia in small bowel transplantation, which can be prevented by the neuropeptide bombesin. 2006 Jul-Aug Transplant. Proc. pmid:16908293
Mayer AD Four-year follow-up of the European Tacrolimus Multicenter Renal Study. 1999 Transplant. Proc. pmid:10576038
Farghali H et al. A biochemical and 31P-NMR investigation of the effect of FK 506 and cyclosporine pretreatment on immobilized hepatocytes perifused with ethanol. 1991 Transplant. Proc. pmid:1721284
Harrison DM et al. Reduction in hospital stay after liver transplantation. 1996 Transplant. Proc. pmid:8623451
Kaplinsky E et al. Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients. 2012 Transplant. Proc. pmid:23146455
Barten MJ et al. Pharmacodynamic monitoring of the conversion of cyclosporine to tacrolimus in heart and lung transplant recipients. 2005 Transplant. Proc. pmid:16387162
Chueh SC et al. Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients. 2004 Transplant. Proc. pmid:15518745
Schulz T et al. Tacrolimus/mycophenolate mofetil/steroid-based immunosuppression after pancreas-kidney transplantation with single shot antithymocyte globulin. 1998 Transplant. Proc. pmid:9636623
Pan F et al. FK 506 prolongs survival of liver but not heart mouse-to-rat vascularized xenografts. 1994 Transplant. Proc. pmid:7518113
Villamil F et al. Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine. 2006 Transplant. Proc. pmid:17112875
Söderdahl G et al. FK 506 improves recovery of bile secretion following orthotopic liver transplantation in man. 1995 Transplant. Proc. pmid:7533362
Wang CH et al. The impact on biochemical profiles and allograft function for patients converted from cyclosporine to tacrolimus after clinical heart transplantation. 2008 Transplant. Proc. pmid:18929812
Wynn C et al. High level of TGF-beta in organ transplantation might be due to rejection rather than calcineurin inhibitor medication. 2002 Transplant. Proc. pmid:12176408
Li J et al. Regulatory effect of FK506 on CD152 and PD-1 in the liver allorecipients. 2008 Transplant. Proc. pmid:18589137
Ochiai T et al. Japanese multicenter studies of FK 506 in renal transplantation. Japanese FK 506 Study Group. 1995 Transplant. Proc. pmid:7533419
Takaya S et al. Retransplantation of liver: a comparison of FK 506- and cyclosporine-treated patients. 1991 Transplant. Proc. pmid:1721348
Cardinal H et al. The evolution of kidney function after lung transplantation: a retrospective cohort study. 2009 Transplant. Proc. pmid:19857746
Ronchetti F et al. Mucosal hyaluronic acid quantification in small bowel transplantation in pigs. 1996 Transplant. Proc. pmid:8907950
Sun CK et al. Intensive care after orthotopic liver transplantation. 1994 Transplant. Proc. pmid:7520627
Yin DP et al. Efficacy of FK506, leflunomide, anti-CD4, and CTLA4IG treatments in rat to mouse pancreas xenograft transplantation. 2000 Transplant. Proc. pmid:10936320
Prasad SJ et al. In vitro effects of cyclosporine and FK 506 on the renal cortex. 1991 Transplant. Proc. pmid:1721380
Witzigmann H et al. Immunosuppression with sirolimus/tacrolimus combination in pancreas transplantation: 1-year results. 2002 Transplant. Proc. pmid:12493472
Kusne S et al. Early infections in kidney transplant recipients under FK 506. 1991 Transplant. Proc. pmid:1703364
Nanmoku K et al. Effects of immunosuppressants on the progression of hepatitis C in hepatitis C virus-positive renal transplantation and the usefulness of interferon therapy. 2008 Transplant. Proc. pmid:18790241
Citterio F et al. Conversion to tacrolimus immunosuppression in renal transplant recipients: 12-month follow-up. 2002 Transplant. Proc. pmid:12176535
Terakura M et al. Effects of peritransplant administration of hematopoietic growth factors on the development of chronic allograft rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083380
Hariharan S et al. Long-term renal and pancreas function with tacrolimus rescue therapy following kidney/pancreas transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123462
Jonas S et al. Posttransplant malignancy and newer immunosuppressive protocols after liver transplantation. 1996 Transplant. Proc. pmid:8962257
Madariaga JR et al. The long-term efficacy of multivisceral transplantation. 2000 Transplant. Proc. pmid:10995918
Tze WJ et al. Long-term survival of islet allografts in diabetic rats treated with FK 506. 1991 Transplant. Proc. pmid:1721411
Shinozuka N et al. Correlation between simplified immunocompetence assay and clinical graft states in kidney or liver transplant recipients. 1996 Transplant. Proc. pmid:8658649
Ju MK et al. Is the affinity column-mediated immunoassay method suitable as an alternative to the microparticle enzyme immunoassay method as a blood tacrolimus assay? 2008 Transplant. Proc. pmid:19100463
McCarter JF et al. FK 506 protects brain tissue in animal models of stroke. 2001 Transplant. Proc. pmid:11377571
Baran DA et al. Predictors of early renal insufficiency in cardiac transplant recipients initiated on tacrolimus. 2002 Transplant. Proc. pmid:12176609
Kauffman HM et al. Drug regimens affect cadaveric kidney graft survival. 2001 Feb-Mar Transplant. Proc. pmid:11267176
Navaneethan SD et al. Tacrolimus-associated hypomagnesemia in renal transplant recipients. 2006 Transplant. Proc. pmid:16797291
Ettenger RB New immunosuppressive agents in pediatric renal transplantation. 1998 Transplant. Proc. pmid:9723350
Chu Z et al. Influence of immunosuppressive drugs on the development of CD4(+)CD25(high) Foxp3(+) T cells in liver transplant recipients. 2010 Transplant. Proc. pmid:20832552
Hasegawa S et al. FK 506 and cyclosporine: effects and side effects in canine lung transplantation. 1991 Transplant. Proc. pmid:1721443
Groth CG et al. New immunosuppressive drugs in transplantation. 1993 Transplant. Proc. pmid:7689274
Thiru S et al. Pathological studies in canine and baboon renal allograft recipients immunosuppressed with FK-506. 1987 Transplant. Proc. pmid:2445086
Morales J et al. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells. 2008 Transplant. Proc. pmid:19010240
Wang CH et al. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral. 2004 Transplant. Proc. pmid:15561257
van den Berg AP et al. Recurrent HCV infection reduces the requirement for tacrolimus after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267375
Escartín A et al. Orthotopic small bowel transplantation in pigs without steroids. 1999 Transplant. Proc. pmid:10500720
Hutchinson IV et al. Differences in the mode of action of cyclosporine and FK 506. 1998 Transplant. Proc. pmid:9636388
Budde K et al. Tacrolimus rescue therapy in late rejection after renal transplantation: outcome after 18 months. 1998 Transplant. Proc. pmid:9636503